Bicycle Therapeutics Q3 2026 earnings

BCYC · 2026-10-29 07:05 BMO ET · 8-K on SEC · 10-Q on SEC

Loss narrowed significantly as collaboration revenue surged and operating expenses declined, supported by a favorable tax rate.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$34.1M+190%+441%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $47.5M (-38% YoY)
  • One-offs in the quarter Provision for income taxes $1.2M (vs -$1.1M prior year)
  • Effective tax rate 11% (vs -2% prior year)
  • Non-GAAP bridge No reconciliation provided in this release.

KPIs

MetricActualPrior quarterPrior yearChange
Collaboration revenue$34.1M$629K$11.7M+441% QoQ, +190% YoY
R&D expenses$33.4M$41.2M$58.4M-19% QoQ, -43% YoY
G&A expenses$14.1M$14.0M$18.9M0% QoQ, -25% YoY
Cash and cash equivalents$469.9M$510.1M$628.1M-8% QoQ, -25% YoY

Guidance

not stated in the 8-K

What drove it

  • Revenue story Collaboration revenue surged to $34.1M, up 190% YoY and 441% QoQ, driven by a new collaboration.
  • EPS story Net loss narrowed to $0.15 per share, driven by higher revenue, lower operating expenses, and a favorable tax rate.
  • One-off check Provision for income taxes of $1.2M (vs -$1.1M prior year).

The good

  • Loss narrowed to $0.15 per share from $0.85 YoY.
  • Collaboration revenue surged to $34.1M (+190% YoY).
  • Operating expenses declined 38% YoY to $47.5M.
  • Cash runway extended to 2030.

The bad

  • Net loss remains significant at $10.5M.
  • Cash balance declined 8% QoQ to $469.9M.

The ugly

  • none

Open questions

  • What specific collaboration drove the surge in revenue?
  • What specific drivers caused the 8% QoQ decline in cash balance?
Full release

Earnings: BCYC — filed 2026-10-29

Bicycle Therapeutics Plc (BCYC) · Form 8-K, Item 2.02 · Filed · SEC filing

Bicycle Therapeutics Reports Recent Business

Progress and Third Quarter 2026 Financial Results

Nuzefatide pevedotin granted FDA Orphan Drug

Designation for the treatment of pancreatic cancer; further updates expected in 2027

Initiation of the first company-sponsored radioligand clinical trial for BT1702, an MT1-MMP- targeting Bicycle®

Radioconjugate, expected in 2H 2027

Cash and cash equivalents of $469.9 million as of September 30, 2026, with expected cash runway into 2030

CAMBRIDGE, England & BOSTON, October 29, 2026

- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate updates.

“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands. We believe the FDA’s Orphan Drug Designation for nuzefatide in pancreatic cancer further supports our development strategy and underscores the significant unmet need in this patient population,” said Bicycle CEO Kevin Lee, Ph.D. “We remain focused on disciplined execution across our prioritized programs and believe our growing clinical data continue to demonstrate the potential of Bicycle® molecules to deliver highly targeted therapies with differentiated benefit/risk profiles. We look forward to advancing our pipeline and reaching important clinical milestones for nuzefatide and initiating our first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027.”

Third Quarter 2026 and Recent Events

Bicycle Therapeutics is actively enrolling patients in a Phase 2 clinical trial to evaluate efficacy, safety, and pharmacokinetics of nuzefatide in adult patients with recurrent pancreatic ductal adenocarcinoma (PDAC) and expects to provide further updates in 2027.

Third Quarter 2026 Financial Results

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle®

Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle®

Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.

Bicycle Therapeutics is headquartered in Cambridge,

UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended — (Unaudited)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Collaboration revenue34,05711,73435,57324,631
Operating expenses:
Research and development33,42258,426123,483188,513
General and administrative14,11218,85945,60858,475
Total operating expenses47,53477,285169,091246,988
Loss from operations-13,477-65,551-133,518-222,357
Other income (expense):
Interest and other income4,2136,70013,45022,587
Interest expense-45-44-137-149
Total other income, net4,1686,65613,31322,438
Net loss before income tax provision-9,309-58,895-120,205-199,919
Provision for (benefit from) income taxes1,1692051,431-1,113
Net loss-10,478-59,100-121,636-198,806
Net loss per share, basic and diluted-0.15-0.85-1.74-2.87
Weighted average ordinary shares outstanding, basic and diluted69,979,93469,303,74669,823,83069,251,291

Balance Sheet

September 30, — (Unaudited) (in thousands)

September 30, – 2026December 31, – 2025
Cash and cash equivalents469,928628,110
Working capital493,097625,901
Total assets567,179717,597
Total shareholders’ equity505,277609,977

Cash Flow

From the 10-Q · Nine Months Ended — (Unaudited)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Cash flows from operating activities:
Net loss-121,636-198,806
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense18,75227,811
Depreciation and amortization3,2695,086
Deferred income tax provision (benefit)792-1,693
Changes in operating assets and liabilities:
Research and development incentives receivable-17,394-28,395
Prepaid expenses and other assets3,228-9,946
Operating lease right‑of‑use assets2,2963,407
Accounts payable-216-3,990
Accrued expenses and other current liabilities-7,6782,093
Operating lease liabilities-2,526-4,046
Deferred revenue-34,720-21,850
Net cash used in operating activities-155,833-230,329
Cash flows from investing activities:
Purchases of property and equipment-1,283-1,776
Net cash used in investing activities-1,283-1,776
Cash flows from financing activities:
Proceeds from the exercise of share options and settlement of restricted share units164
Payments of finance lease obligations-151-120
Net cash used in financing activities-135-116
Effect of exchange rate changes on cash, cash equivalents and restricted cash-1,4791,026
Net decrease in cash, cash equivalents and restricted cash-158,730-231,195
Cash, cash equivalents and restricted cash at beginning of period628,715880,067
Cash, cash equivalents and restricted cash at end of period469,985648,872

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation

Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,”

“could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,”

“may,” “plans,” “possible,” “promising,” “potential,” “seeks,”

“will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of nuzefatide pevedotin, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and the potential development of nuzefatide pevedotin in pancreatic cancer; the clinical and regulatory benefits anticipated from the Orphan Drug Designation granted to nuzefatide pevedotin, including the potential for seven years of market exclusivity upon regulatory approval, eligibility for tax credits and exemption from certain FDA user fees; the progress of Bicycle Therapeutics’ clinical trials, reporting data from Bicycle Therapeutics’ clinical trials, including for nuzefatide pevedotin, and updates on future clinical development plans for nuzefatide pevedotin; the potential of Bicycle molecules to deliver highly targeted therapies with differentiated benefit/risk profiles; the positive properties of Bicycle® radioligand molecules for radiopharmaceutical use; the development of the Bicycle® radioligands pipeline, including BRCs, and the expected initiation of the first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027; communications with and feedback from the FDA and other regulatory agencies; Bicycle Therapeutics’ expected financial runway; and the use of Bicycle

Therapeutics’ technology through various partnerships to develop therapies for diseases in additional therapeutic areas. Bicycle

Therapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions... (truncated)ng statements as a result of various factors, including: uncertainties related to the benefits and potential unintended consequences of the strategic reprioritization and recent workforce reductions; uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics may not realize the intended benefits of its technology or partnerships; the risk that Bicycle Therapeutics may not achieve any of its clinical development strategies; timing of results from clinical trials; whether the outcomes of preclinical studies and prior clinical trials will be predictive of future clinical trial results; the risk that trials may have unsatisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle Therapeutics’ product candidates; the risk that Bicycle Therapeutics’ projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle Therapeutics’ actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk

Factors” in Bicycle Therapeutics’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on

July 30, 2026, as well as in other filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Bicycle Therapeutics plc

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

Balance Sheets

Data

(In thousands)

(Unaudited)

Investors:

Matthew DeYoung

Argot Partners ir@bicycletx.com

212-600-1902

Media:

Argot Partners media@bicycletx.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Bicycle Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.